Stark tillväxt Omsättningen i Q2’22 uppgick till 35 mkr (21) vilket innebär en tillväxt om 66% varav...
Pro forma growth in line with company target Margin slightly pressured by virtual care acquisitions...
Redeye comments on Pila Pharma’s Q2 report. Highlights from the quarter include receiving ODD for XE...
Redeye comments on TH1NG’s Q2 report, which was below our expectations in terms of revenues but also...
Redeye comments on Kontigo Care’s Q2’22 report where sales came in slightly higher than we estimated...
Projektportföljen fortsätter växa för vindkraftbolaget och utöver det har Heixon vunnit en viktig ak...
Redeye considers I-Tech’s Q2 figures strong, beating our estimates across the board.
Fellow Bank’s H1 figures were weak due to ECL changes driven by the loan book growth and non-recurri...
New facility receives GMP certification Developed first formulations with mAbs Neutral share price r...
Redeye comments on Safello's Q2'22 report, which was impacted by a weaker crypto market.
Redeye states that the Q2 report was weaker than expected but still shows AVTECH is back on a solid ...
Redeye concludes that Q2 was in line with sales estimates but included a higher cost base than expec...
Redeye updates its estimates and valuation for Better Collective post Q2-results where revenue was i...
Redeye comments on yesterday’s Q2 report from Vicore, which came in as expected.
Redeye is still positive on the case as we believe the long-term potential offers good risk reward.
Vow reported strong headline figures across the board for H1.
Redeye comments on 2cureX’s Q2’22 report. Operational activities are progressing well, laying the fu...
Utvecklingsbolaget Tendo redovisade som förväntat ingen omsättning under det andra kvartalet.
Den 25 augusti 2022 publicerade Aptahem sin delårsrapport för andra kvartalet 2022.
Q2 sales +6% above ABGSCe We make positive revisions on the back of the report Good start to Q3, mon...
